KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $2.3 million.

  • Supernus Pharmaceuticals' Non Operating Income fell 4443.63% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 2265.95%. This contributed to the annual value of $16.2 million for FY2024, which is 5501.77% up from last year.
  • Supernus Pharmaceuticals' Non Operating Income amounted to $2.3 million in Q3 2025, which was down 4443.63% from $4.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Non Operating Income's 5-year high stood at $14.7 million during Q1 2022, with a 5-year trough of -$4.0 million in Q4 2021.
  • Moreover, its 5-year median value for Non Operating Income was $2.8 million (2022), whereas its average is $2.8 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Non Operating Income tumbled by 13849.14% in 2021 and then skyrocketed by 28557.19% in 2022.
  • Supernus Pharmaceuticals' Non Operating Income (Quarter) stood at -$4.0 million in 2021, then soared by 159.3% to $2.4 million in 2022, then decreased by 17.25% to $2.0 million in 2023, then skyrocketed by 150.6% to $5.0 million in 2024, then tumbled by 54.25% to $2.3 million in 2025.
  • Its Non Operating Income stands at $2.3 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.4 million for Q1 2025.